Journal of Hepatology

Article	Citations
THU-192 Liver steatosis assessed by controlled attenuation parameter in patients with primary biliary cholangitis	3346
JHEP at a glance (October 2024)	2041
MetALD accounts for a large part of what we call MASLD!	1937
SAT-521 Impact of centre type on treatment and survival outcomes in hepatocellular carcinoma (HCC)	1567
FRI-247 Association of plasma magnesium with MASH and cirrhosis: combined data from multiple therapeutic trials including more than 10, 000 patients	1508
THU-457 Outcome of liver transplantation in patients with hepatocellular carcinoma previously treated with immune checkpoint inhibitorbased therapy-first results from an international multicenter regi	1258
OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: t	1011
FRI-195 Genetically determined circulating protein biomarkers and risk of advanced fibrosis	507
WED-257 FibroScan compared to liver biopsy for accurately detecting recurrent hepatic steatosis and fibrosis after liver transplantation for metabolic dysfunction-associated steatohepatitis	492
WED-092 Hyperuricemia leads to early cognitive dysfunction and neuronal cell injury in bile-duct ligated rats	408
THU-447 Incidence and predictors of complications following percutaneous liver biopsy: a multicenter study	333
WED-495 The impact of integration and decentralization of HBV services on enhancing the HBV care continuum: an interrupted time series	326
TOP-311-YI Subtypes of steatotic liver disease have differing clinical outcomes	326
OS-004 Testing for hepatitis C virus infection in prisons in England: room for improvement	317
FRI-475-YI NADPH oxidase 1 inhibition as therapeutic strategy in hepatocellular carcinoma: insights from human-relevant models	308
SAT-151-YI The role of interleukin-8 in primary sclerosing cholangitisassociated immune cell dysregulation	293
WED-058-YI High shear stress induced PIEZO1 activation promotes cytoskeleton remodelling and a nuclear deformation develops pro-thrombotic microenvironment and contributes to portal hypertension	278
OS-111 Predictive genomic biomarkers for Atezolizumab plus Bevacizumab combination immunotherapy response in liver cancer: insights from the IMbrave150 trial	275
SAT-479-YI Lower frequency of PNPLA3 in african populations and divergent associations with hepatocellular carcinoma	273
THU-099-YI Small duct primary sclerosing cholangitis is not associated with a heightened risk of colorectal cancer compared to inflammatory bowel disease alone	264
THU-219 Inhibition of HSD17B13 by INI-822 phenocopies the hepatic lipidomic profile of humans with the protective allele	262
SAT-070 Argon plasma coagulation or endoscopic band ligation for gastric antral vascular ectasia: a randomized comparative analysis	258
THU-114 Alkaline phosphatase levels at 6 months as a predictor of response to ursodeoxycholic acid at 1 year in patients with primary biliary cholangitis	248
FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis	232
THU-040-YI Establishment of the irish hepatology nurses association: an association for nurses working in liver disease in Ireland	231

SAT-009 Increased prevalence of metabolic-alcohol liver disease in Europe and of metabolic dysfunction-associated steatotic liver disease in the Americas. Results of the global IMPROVEMENT study	231
WED-524-YI Multi-omics study of chronic liver diseases with rifaximin treatment	230
FRI-067 Impact of Farnesoid X receptor polymorphisms on prognosis in hepatocellular carcinoma	228
SAT-418 Prevalence of hepatitis C virus infection in a nursing home: a frequently overlooked submerged population	226
FRI-245 Longitudinal follow-up of Fib-4 in patients at risk of steatotic liver disease (SLD) receiving low-dose Methotrexate treatment (LDMTX): results from the CIRT randomized placebo-controlled Tria	224
SAT-194 Effect of statin therapy in patients with obesity and cirrhosis secondary to metabolic dysfunction-associated steatotic liver disease (MASLD) on pre-liver transplant mortality	223
THU-093 Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid	220
WED-483 Performance comparison of four hepatitis E antibodies detection methods	220
FRI-470 Deciphering the role of FXR in the rewiring of Treg polarization in hepatocellular carcinoma	217
SAT-041 Real-world evidence of magnesium isoglycyrrhizinate for perioperative protection against hepatic injury in patients undergoing hepatectomy	215
THU-405 Analysis of a decentralized model interdisciplinary for the elimination of HCV in vulnerable population in the province of Huelva (Spain). To continue advancing in the elimination of hepatitis	205
THU-087 Herpesvirus viremia-cause or consequence of ACLF? Higher prevalence of cytomegalovirus, Epstein-Barr virus and herpes simplex virus viremia in patients with acute-on-chronic liver failure	205
WED-439 Linkage of anti‐HCV reactive persons to HCV care and treatment services in Georgia	203
WED-548 Rifaximin-alpha acts through increased abundance of Lactobacillus spp. in murine models of chronic liver disease	198
FRI-258 No evidence for viral escape mutations in immunodominant HCV-specific CD4 T cell epitopes	189
FRI-260 Identification of hepatitis B virus epitopes presented by human leukocyte antigen A*11:01 as potential targets for immunotherapy	187
THU-270 HBV genotype association with response to xalnesiran in nucleos (t)ide analogue treated participants with chronic hepatitis B infection in the Piranga phase 2 platform study	183
OS-020 Reviewing the utility of genetic cholestasis testing in adults with cholestatic liver disease	179
LBP-003 DR10624, a first-in-class, FGF21 receptor (FGF21R)/glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) triple agonist rapidly and significantly reduced liver fat in obese subjects with modest hyp	178
OS-044 Liver sinusoidal endothelial cell BRD4 drives inflammatory angiocrine signaling in liver fibrosis	176
FRI-144 Abrogation of hepatic TRb action protects the liver from acute liver injury	175
THU-489 Disruption of receptor-interacting protein kinase 1 post-translational modifications in alcohol-associated liver disease	169
LBP-015 Comparison of endoscopic ultrasound portosystemic gradient with HVPG and direct porto-systemic pressure gradient measurements	167
OS-075 Dual plasma molecular adsorption system therapy in patients with acute-on-chronic liver failure: a non-randomized clustercontrolled study (PADSTONE)	165
FRI-166 Real-world evidence on clinical outcomes and microbiome changes after healthy donor stool transplantation as palliative therapy compared to best supportive care in patients with unstable decom	165
FRI-161 Single-cell RNA sequencing reveals a fundamental role of LCN2+ neutrophils in the innate immune response in drug-induced acute-on-chronic liver failure	160
WED-086 Clinical evaluation of multimarker algorithmic scores for detection of early stage hepatocellular carcinoma in high-risk liver patients	160
WED-083 Role of Child-Turcotte-Pugh and ALBI scores in patients with non-cirrhotic hepatocellular carcinoma	158
WED-153 A patient charter for hepatocellular carcinoma: a co-created community call for action on equitable access to early diagnosis and multidisciplinary care	158
WED-262 Prolonged cholestasis following hepatitis A : what lies beneath	155
SAT-113 The intratumoral microbiome in HCC and its impact on treatment response	155
SAT-367 UNITED study: results of the up-titration phase of an open label, multicenter, prospective study to characterize the pharmacokinetics and pharmacodynamics of trientine dihydrochloride and to i	151
FRI-247 In vitro characterization of elebsiran (VIR-2218), an investigational siRNA therapeutic targeting hepatitis B virus	151
THU-069 A composite score of PRO-C6 and platelet count is prognostic for liver-related outcomes in patients with chronic hepatitis C	150
SAT-162 Epidemiology and Risk factors for development of AKI-HRS based on the new consensus definition	150
FRI-044 Dynamic adaptations of CD8+γδ T cells in acute and chronic hepatitis E virus infection	150
TOP-072-YI Human cirrhotic ascites contains myeloid reprogrammed T-cells capable of enhancing peritoneal immune surveillance	147
WED-164 Cirrhotic patients with acute variceal bleeding and an indication for preemptive-TIPS: real-life results	147
WED-184 Assessment of impact of ascitic fluid polymorphonuclear count on development of spontaneous bacterial peritonitis and survival in patients with liver cirrhosis and ascites	147
FRI-036 Single nucleotide polymorphisms of the vitamin D receptor and their impact on vitamin D- and Interleukin-6 levels in liver cirrhosis and acute-on-chronic-liver failure	141
SAT-205 Dynopenia predicts mortality in patients with liver cirrhosis and hepatocellular carcinoma	138
TOP-508 Derivation and validation of a new donor risk score incorporating graft steatosis and donor diabetes mellitus	138
SAT-178 Quantitative measurements of prothrombin in patients with cirrhosis and ascites: a validation study	136
THU-133-YI Risk of hypoglycemia in people with cirrhosis without diabetes	136
FRI-062 Trained human bone marrow mesenchymal stem cells enhance immunoregulatory responses and alleviate ConA-induced acute liver failure	135
FRI-481 Feasibility and effectiveness of liver transplantation following immunotherapy in patients with hepatocellular carcinoma	134
FRI-328 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes	131
WED-121 Comparison of clinical characteristics, risk factors and prognosis of HCC patients with lean and non-lean MASLD undergoing surgical resection	131
THU-334 Cholestasis as a predictor of PSC in inflammatory bowel disease: insights from a romanian cohort study	131
SAT-136-YI Identification of prognosis determining risk factors in outpatients with cirrhosis	130

THU-308-YI Long-term evaluation of controlled attenuation parameter for steatosis monitoring in autoimmune hepatitis	130
WED-145 Morphomolecular proliferative disease and microvascular invasion characterize PET-CT positive hepatocellular carcinoma cases: a single-center pilot study	129
THU-178 Siglec-5 is a functional biomarker that contributes to poor prognosis in patients with liver cirrhosis	129
WED-373 Agreement between hepatic histology and non-invasive methods and their ability to detect MASLD/MASH among morbidly obese patients undergoing bariatric surgery: an egyptian crosssectional study	128
WED-367-YI Frequency and risk factors of fibrosis staging discrepancies between transient elastography and liver biopsy in patients with metabolic-associated steatotic liver disease: role of obesity a	128
SAT-436 Efficacy of Imeglimin in MASLD with type 2 diabetes: a multicenter study	127
SAT-417-YI Sex disparities in response to low-carb, high-fat diet in MASLD	127
FRI-407 Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD	126
WED-405 PRO-C4, a biomarker of perisinusoidal fibrosis, is related to cardiometabolic risk factors, steatosis, and liver stiffness	125
WED-490 Ultrasound-derived visceral adipose tissue: an easily obtainable adiposity index strongly associated with metabolic dysfunctionassociated steatotic liver disease and metabolic parameters	122
FRI-335 Therapeutic potential of a GHRH analog in experimental MASLD	121
FRI-010 Economic evaluation of biomarker-base surveillance for hepatocellular carcinoma in thai patients with compensated liver cirrhosis	120
TOP-016 Genetic determinants of hepatitis B surface antibody disappearance in Taiwan’s vaccinated generations: a genome- wide association study	119
THU-405 Impact of ultra processed foods on metabolic dysfunctionassociated steatotic liver disease: limitations of the NOVA classification	117
TOP-505 Evaluation of a non-invasive pathway for advanced fibrosis detection and liver-related outcomes prognosis in the general population from China, United Kingdom, and United States	115
WED-279 No DDI between Bemnifosbuvir/Ruzasvir and Bictegravir/ Emtricitabine/Tenofovir Alafenamide	115
FRI-024 Living with liver disease: patient and carer experiences in the United Kingdom	115
Submit your late-breaker abstract for the EASL Congress 2024 between 27 March - 10 April	115
The space of Mall confirmed in humans: A response to “Portal venous branches as an anatomic railroad for a gut-bile duct axis”	114
Sign up to EASL Campus: your open-access eLearning Hub	113
Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis	113
The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease	112
Dual effects of brown-fat activation limit hepatocellular carcinoma (HCC) progress in steatotic liver	112
Genomics on the road to functional cure of hepatitis B	111
Reply to: “A comment on `A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B’”	110
Automation of hepatitis C screening through electronic health record algorithm	108
Novel anti-cholestatic treatment strategies by combining inhibition of the Apical sodium-dependent bile acid transporter with stimulation of urinary bile salt excretion or lowering bile salt synthesis	107
Preclinical pharmacology of low molecular weight GLP-1 receptor agonist XW014	106
Portal venous branches as an anatomic railroad for a gut-bile duct-axis	106
Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination	104
Combination of systemic immune-inflammation index and albumin-bilirubin score predict prognosis of sequential therapy with sorafenib and regorafenib in unresectable hepatocellular carcinoma	104
Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy	103
Radiowater perfusion PETof the liver, and its value as a biomarker to discriminate between NAFLD and NASH, and activity and fibrosis grade	103
CyberLiver Animal Recognition Test (CL-ART): a novel remote monitoring tool to assess minimal hepatic encephalopathy	103
Gadoxetic acid-enhanced MRI-derived Functional Liver Imaging Score (FLIS) and spleen diameter provide complementary information for risk stratification in ACLD	103
Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States	102
Lack of fibrosis remodelling in chronic hepatitis C post SVR, as demostrated by YKL-40, is predictive of hepatocellular carcinoma ocurrence	102
Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study	102
Safety, pharmacokinetics, and antiviral activity of the S-antigen Transport Inhibiting Oligonucleotide Polymers (STOPS) drug candidate ALG-010133 in subjects with chronic hepatitis B	102
Full-length genome characterization of inherently resistant african HCV genotype 1, subtype 1l in patients failing DAA-based therapy	101
TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD	100
Multiplex immunostaining and transcriptomic profiling identify novel immune cell markers for non-alcoholic steatohepatitis and primary sclerosing cholangitis	100
Online education significantly improved gastroenterologists’ knowledge of the diagnostic and monitoring techniques used in liver fibrosis	100
Corrigendum to: ‘Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis’ [J Hepatol (2019) 722-734]	100
Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial	98
One stone, two birds: circACTN4, a nexus for a coordinated activation of Hippo and Wnt/β-catenin pathways in cholangiocarcinoma	97
Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease	95
PNPLA3 rs738409 G allele increases the risk of liver cirrhosis in SERPINA1 MZ heterogygotes	95
Evaluating pruritus and fatigue in patients with treatment-refractory primary biliary cholangitis	95
Non-alcoholic fatty liver disease features a reduced reverse polyunsaturated fatty acid transport (free fatty acids/high-density lipoprotein) from the periphery to the liver	94
The regulatory protein and gene expression profile of skeletal muscle in chronic liver disease patients	93
Prevalence and predictors of HDV viremia in anti-HDV positive patients of the HEllenic multicenter ReAl-life CLInical Study (HERACLIS-HDV)	93
Viral like particle analysis shows changes with PPIs and may be more sensitive than metagenomics to study PPI modulation of virome in cirrhosis	93
Feasibility of a home-based, virtually-delivered, group exercise intervention in older patients with liver cancer (TELEX-Liver Cancer)	93
Exacerbated response to patterned injury in the cirrhotic liver: potential susceptibility to ischemia	91
The discovery of AMS-I-1274, a high potent and orally active capsid-assembly modulator against hepatitis B virus	90
Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)	90
Factors associated with HCC stage at presentation and survival in an ethnically diverse UK population	90
Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm	89
The impact of liver function improvement after direct-acting antiviral therapy on the outcome in hepatitis C virus patients with decompensated cirrhosis	89
Hepatitis C seroconversion rates among individuals with repeated testing-Georgia, 2017–2021	89
Bacterial infections in cirrhosis are associated with reduction in gut microbial phage-bacterial interactions	89
Viral and ALT kinetics after nucleos (t)ide analogue withdrawal among patients who remain off-therapy: results from a global, multi-ethnic cohort of chronic hepatitis B patients (RETRACT-B study)	88
The health economic outcomes of trial ACTG5360/MINMON	87
Micro-elimination of chronic hepatitis C virus in patients with psychiatric disorders: a multidisciplinary strategy in the outpatient mental health center	87
Suboptimal virological response to antiviral therapy in chronic hepatitis B as an independent predictor for occurrence of HCC and development of severe liver events	87
Liver transplantation for patients with fibrolamellar hepatocellular carcinoma: a comprehensive multicenter analysis to support future decision making	87
Multiplexed digital spatial protein profiling reveals potential non-invasive biomarkers to predict advanced fibrosis	86
Effectiveness of MRI methods in the assessment of hepatic steatosis in living liver donors	86
Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study	86
HBV infection reshapes host chromatin accessibility and affects choline and iron metabolism	85
Development of a high precision liver biopsy method to improve the accuracy of fibrosis staging and collagen profiling	85
Oral antibiotic treatment protects mice against the development of diet-induced non-alcoholic fatty liver disease but not against diet-induced intestinal barrier dysfunction	84
Molecular epidemiology of hepatitis B virus and hepatitis delta virus coinfection in-Sudan	84
Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece	84
Genetic modifiers of liver phenotypes in pediatric Wilson disease: liver biopsy and transient elastography based study	83
Effect of housing temperature on non-alcoholic fatty liver disease development in C57BL/6N mice	83
Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis	82
Endoscopic glue injection v/s endoscopic human thrombin injection for bleeding gastric varics -a randomized controlled trial	82
Temporal trajectory of the model for end-stage liver disease (MELD) score for prediction of mortality among patients with liver cirrhosis	82

Beneficial effect of cystic fibrosis transmembrane conductance regulator modulators on adults with cystic fibrosis liver disease	81
miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC	80
Causes of death by fibrosis stage in 959 biopsy-proven NAFLD patients	80
Comparable risk of hepatocellular carcinoma between immune-tolerant and active phase in hepatitis B e antigen-positive patients	80
Neutrophil gelatinase-associated lipocalin predicts response to terlipressin and albumin in patients with hepatorenal syndrome	79
Outcomes of pregnancy in patients with autoimmune hepatitis in the Netherlands	79
Diagnostic accuracy of MRE for staging hepatic fibrosis in patients with NAFLD	78
Sofosbuvir/Velpatasvir/Voxilaprevir for re-treatment in direct-acting antiviral experienced hepatitis C virus patients: a systematic review and meta-analysis	78
Association between liver cirrhosis and cardiovascular events in a large German cohort-a population based study	78
Acute liver failure due neonatal hemochromatosis: case with fatal outcome despite early diagnosis and treatment	78
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations	78
Assessing progress towards achieving regional hepatitis B control goal-nationwide serosurvey among children, Uzbekistan, 2022	77
Disclosures: commercial relationships	77
Alcohol use disorder in patients undergoing bariatric surgery is associated with a worse prognosis	77
Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)	76
Inclusion of the fatty liver-associated variants in the clinical workup of patients: results of an eight years’ experience in a tertiary referral center with genotyping facility	76
Outcomes between surgical resection and transarterial chemoembolization in patients with multifocal BCLC-A and Child-Pugh B	76
Improvement of hepatic and extrahepatic functions and anti-inflammatory effects of nitazoxanide in disease models of LPS-induced systemic inflammation and acute-on-chronic liver failure	75
Reply to: Correspondence on “EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update”	75
No effect of HBsAg positivity on antibody response after COVID-19 vaccine	74
Diagnosis and pathophysiological analysis of sarcopenia using liver MR in chronic liver disease	74
Reversal of epithelial-mesenchymal transition in a cholangiocarcinoma cell line by genetic targeting of sulfatide synthesis	73
Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study	72
Eliminating viral hepatitis one island at a time-the Hainan experience	72
Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study	72
Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis	71
Booster SARS-CoV-2 vaccination elicits robust antibody response to wild type but not Omicron subvariants BA.4/5 in patients with cirrhosis	71
Reply to: “Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices”	71
Gut-liver crosstalk in hepatocellular carcinoma and non-selective beta-blockers: is there a link?	71
Influence of language barrier and cultural differences in hepatitis B disease knowledge in the chinese community of Barcelona	70
Circadian sleep-wake rhythms in non-alcoholic fatty liver disease	69
Production of reactive oxidant species and fatty acid uptake is increased in regulatory T-cells in autoimmune hepatitis, and associated with down-regulation of markers linked to suppressor function	69
Sarcopenia at listing for liver transplantation is a negative predictor for post-transplant survival, but not for graft survival	69
The gut (and its microbiota)-liver axis in liver disease associated with alpha-1-antitrypsin deficiency	69
The anti-fibrotic efficacy of Adelmidrol depends in the level of hepatic PPAR gama	69
Digital pathology using stain-free imaging indices allows direct prediction of all-cause mortality, hepatic decompensation and hepatocellular carcinoma development in patients with non-alcoholic fatty	68
APRI+ALBI score is superior to Indocyanine Green (ICG) clearance and LiMAx test in the prediction of posthepatectomy liver failure-an international multicenter study of 14581 patients	68
Exploration of the lack of systematic surveillance for hepatocellular carcinoma for patients with non-alcoholic fatty liver disease	68
A new nuclear-erythroid-2-related factor 2 activator for the treatment of non-alcoholic steatohepatitis: evidence of metabolic and anti-fibroinflammatory effects in human precision cut liver slices	68
Hepatocyte senescence is linked with extrahepatic organ injury, failure of regeneration and mortality in patients with acute indeterminate hepatitis	67
Perturbation of rhythmicity of the circadian clock-oscillator in hepatic stellate cells is associated with liver fibrosis	67
Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis	66
HCV micro-elimination strategy in a tertiary hospital: identification of lost cases and linkage to care	66
Policy and implementation needs for hepatitis B birth dose in the WHO African region: a survey of national program managers	66
An explainable artificial intelligence model for prediction of high-risk non-alcoholic steatohepatitis	66
Assessment of hepatic fibrosis screening in primary care using the FIB-4 score, followed in second line by an ELF (Enhanced liver Fibrosis) test	66
HBsAg kinetics at month 9 after analogue treatment discontinuation in chronic hepatitis B eAg (-) predicts long-term HBV control	66
Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)	65
Association of liver fibrosis and hypophosphatemia in treatment-naïve patients with chronic hepatitis B	65
HDV genotypes have an impact on pegylated interferon therapy response and long-term liver disease related outcomes	65
A gene editing approach for chronic hepatitis B: elimination of hepatitis B virus in vivo by targeting cccDNA and integrated viral genomes with a sequence-specific ARCUS nuclease	64
Methodological challenges in studying immune-suppressive neutrophils in HCC models	64
The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry	64
The PNPLA3 genotype is the main driver of weight gain after the hepatitis C cure	63
THU-113 Optimizing thiopurine therapy in autoimmune hepatitis (AIH): a multi-center study on monitoring metabolite profiles and co-therapy with allopurinol	62
The LIVERSCREEN project’s goal is to to establish a population-based screening programme for liver fibrosis utilising non-invasive markers	62
WED-511 FIB-4 for identifying chronic liver disease patients requiring HCC surveillance	62
Combination of crafity score with alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma	62
Is MASLD a real culprit for all-cause mortality? A meta-analysis and preliminary pathophysiology exploration in the real world	62
Correspondence on “Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis”	61
LBP-016 Carvedilol versus propranolol in the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis	61
WED-347 Diagnosis of advanced liver fibrosis: the synergy of open data, synthetic data generation, CatBoost, and feature engineering	61
LBP-040 Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interimresults for 2 years from the ASSURE study	61
Rethinking methodology and data integrity in Mendelian randomization: Insights from air pollution and MASLD research	61
RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis	60
GS-012 Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, doubleblind, placebo-controlled, phase 2b trial (SYMMETRY)	60
OS-124 Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH	60
Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients	60
LBP-036 Final results from the phase 3 REGENERATE trial evaluating the effects of obeticholic acid in patients with pre-cirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis	60
Reply to: “Oral bis-choline tetrathiomolybdate rapidly improves copper balance in patients with Wilson disease”	60
Reply to: ‘Exploring hepatocellular carcinoma risks in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe’	60
Register now for the EASL Liver Cancer Summit!	59
Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score	59
Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease	59
Corrigendum to “EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma” [J Hepatol (79) (2023) 181–208]	58
Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab	57
Erratum to ‘Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis’ [J Hepatol 83 (2025) 70–80]	57
Surgical treatment of intrahepatic cholangiocarcinoma	56
What’s next after the 2025 BCLC update?	56
Aberrant ubiquitination causing liver cancer: The ADRM1-ΔEx9- FBXW7 connection	56
Augmenter of liver regeneration: Mitochondrial function and steatohepatitis	55
Molecular profiling and matched targeted treatment in cholangiocarcinoma: results from the Italian dataset (ANITA)	54
PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial	54
Lack of VMP1 impairs hepatic lipoprotein secretion and promotes non-alcoholic steatohepatitis	54
Genetic and non-genetic drivers of histological progression and regression in MASLD	54
Differences between hepatocellular carcinoma caused by alcohol and other aetiologies	54
Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases	53
EASL Clinical Practice Guidelines on TIPS	53
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis	53
Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population	52
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study	52
WED-519-YI Criss-cross fecal microbiota transplant identifies hepatic steroid biosynthesis and linoleic acid metabolism linked with liver injury and dysbiosis in rat	52
Changing epidemiology, global trends and implications for outcomes of NAFLD	52
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update	52
Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease	52